Detection of Bladder CA by Microsatellite Analysis (MSA)
- Helber, Sarah — AIBioTech
- Lerner, Seth P. — Baylor College of Medicine
- Kibel, Adam — Brigham and Womens Hospital
- Loughlin, Kevin R. — Brigham and Womens Hospital
- Jansz, Ken — Burlington Urology
- Moon, Chulso — Cangen Biotechnologies Inc.
- Shore, Neal — CURC/Carolina Urologic Research Center
- Feng, Ziding — Fred Hutchinson Cancer Research Center
- Wessells, Hunter — Harborview Medical Center
- Schoenberg, Mark P. — Johns Hopkins University
- Dineen, Martin — LURN-Daytona Beach
- Berger, Yitzhak — LURN-New Jersey
- Grable, Michael — LURN-Orange City
- Young, Paul — Mayo Clinic-Jacksonville
- Dalbagni, Guido — Memorial Sloan-Kettering
- Srivastava, Sudhir — National Cancer Institute
- Neidinger, Erik — National Cancer Institute at Frederick
- Presti, Joseph C. — Stanford University
- Casey, Richard — The Fe/Male Health Clinic
- Barkin, Jack — The Male Health Centre
- Zadra, Joseph — The Male/Female Health and Research Center
- Kamat, Ashish M. — The University of Texas MD Anderson Cancer Cente
- Monnig, William B. — The Urology Group
- Amling, Christopher L — University of Alabama at Birmingham
- Steinberg, Gary D. — University of Chicago Urology Center
- Stass, Sanford — University of Maryland School of Medicine
- Lee, Cheryl T. — University of Michigan
- Messing, Edward — University of Rochester Medical Center
- Basler, Joseph W. — University of Texas Health Science Center San Antonio
- Klotz, Laurence — University of Toronto
- Mathur, Arun — Urotec
Goal 1: To determine sensitivity and specificity of microsatellite analysis (MSA) of urine sediment, using a panel of 15 microsatellite markers, in detecting bladder cancer in participants requiring cystoscopy. This technique will be compared to the diagnostic standard of cystoscopy, as well as to urine cytology. Goal 2: To determine the temporal performance characteristics of microsatellite analysis of urine sediment. Goal 3: To determine which of the 15 individual markers or combination of markers that make up the MSA test are most predictive of the presence of bladder cancer.
No datasets are currently associated with this protocol.